Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-09
2011-08-09
Aeder, Sean (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
07993852
ABSTRACT:
Herein disclosed are methods that are prognostic for neoplastic/preneoplastic disease in a subject vertebrate, wherein said disease is associated with a tissue that normally expresses MN, but which MN expression is lost or diminished upon carcinogenesis. Exemplary of the types of preneoplastic
eoplastic diseases subject to the prognostic methods of this invention are those of gastric mucosa, gallbladder, biliary ducts, and ductal cells of duodenal glands. An exemplary prognostic method comprises comparing the level of MN gene expression product in a tissue sample from the affected subject, with the average MN gene expression product level found in analogous preneoplastic
eoplastic tissue samples; an above average MN gene expression product level indicates poorer prognosis for the subject. MN gene expression products useful in the prognostic methods include MN protein, MN polypeptide, and/or MN nucleic acids.
REFERENCES:
patent: 5387676 (1995-02-01), Zavada et al.
patent: 5989838 (1999-11-01), Zavada et al.
patent: 6004535 (1999-12-01), Zavada et al.
patent: WO 03/089659 (2003-10-01), None
Tockman et al (Cancer Res., 1992, 52:2711s-2718s).
Matsumura et al (Neurol Med Chir, 1997, 37: abstract).
Hicks et al (Urol Int, 2003, 70(3): abstract).
Young et al (Int J Gynecol Pathol, 1992, 11(2): abstract).
Ishizawa et al (Asian Journal of Surgery, Jul. 2006, 29(3):145-148).
Ivanov et al (American Journal of Pathology, 158(3): 905-19)).
Ashida et al., “Effects of von Hippel-Lindau gene mutation and methylation status on expression of transmembrane carbonic anhydrases in renal cell carcinoma,”J Cancer Res Clin Oncol, 128: 561-568 (2002).
Brewer et al., “A Study of Biomarkers in Cervical Carcinoma and Clinical Correlation of the Novel Biomarker MN,”Gynecologic Oncology63: 337-344 (1996).
Bui et al., “Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma: Implications for Prognosis and Therapy,”Clin. Cancer Res., 9: 802-811 (2003).
Chen et al., “Expression of CA9 at the invasion front of gastric cancers,”Gut, 54(7): 920-927 (2005).
Chia et al., “Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma,”J Clin Oncol, 19: 3660-3668 (2001).
Cho et al., “Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma,”Br. J Cancer, 85: 563-567 (2001).
Chrastina et al., “Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma.”Int J Cancer, 105(6): 873-881 (2003).
Giatromanolaki et al. “Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer,”Cancer Res, 61:7992-7998 (2001).
Ivanov et al., “Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.”Am J Path, 158(3): 905-919 (2001).
Juhasz et al., “Expression of carbonic anhydrase IX in human pancreatic cancer,”Aliment Pharmacol Ther, 18: 837-846 (2003).
Karhumaa et al., “Expression of the transmembrane carbonic anhydrases, CA IX and CA XII, in the human male excurrent ducts,”Mol Hum Reprod, 7: 611-616 (2001).
Kivela et al, “Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CA IX and XII, in normal mucosa of large intestine and in colorectal tumors.”Dig Dis Sci, 46(10): 2179-2186 (2001).
Kivela et al., “Expression of transmembrane carbonic anhydrase isozymes IX and XII in normal human pancreas and pancreatic tumours,”Histochem Cell Biol, 114: 197-204 (2000).
Koukourakis et al., “Ilypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy,”Clin Cancer Res, 3399-3403 (2001).
Leppilampi et al., “Carbonic anhydrase isozymes IX and XII in gastric tumors,”World J Gastroenterol, 9: 1398-1403 (2003).
Liao et al. “Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial neoplasia and cervical carcinoma,”Am J Pathol,145: 598-609 (1994).
Loncaster et al., “Carbonic anhydrase expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix,”Cancer Res, 61: 6394-6399 (2001).
Moss et al., “Inward growth of colonic adenomatous polyps,”Gastroenterology, 111: 1425-1432 (1996).
Nishimori et al., “Carbonic anhydrase in human pancreas: hypotheses for the pathophysiological roles of CA isozymes.”Ann N Y Acad Sci., 880: 5-16 (1999).
Ortova Gut et al., “Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9,”Gastroenterology, 123: 1889-1903 (2002).
Parkkila and Parkkila, “Carbonic anhydrase in the alimentary tract. Roles of the different isozymes and salivary factors in the maintenance of optimal conditions in the gastrointestinal canal,”Scand J Gastroenterol., 31: 305-317 (1996).
Parkkila et al., “Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro,”Proc Natl Acad Sci(USA), 97: 2220-2224 (2000).
Pastorek et al., “Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonc anhydrase and a putative helix-loop-helix DNA binding segment,”Oncogene, 9: 2877-2888 (1994).
Pastorekova and Zavada, “Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy,”Cancer Therapy, 2: 245-262 (2004).
Pastorekova et al., “A Novel Quasi-viral Agent, MaTu, Is a Two-Component System,”Virology, 187: 620-626 (1992).
Pastorekova et al., “Carbonic Anhydrase IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts,”Gastroenterology, 112: 398-408 (1997).
Potter and Harris, “Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer,”Br J Cancer, 89: 2-7 (2003).
Risio, M., “Cell proliferation in colorectal tumor progression: an immunohistochemical approach to intermediate biomarkers,”J. Cell Biochem, 16G: 79-87 (1992).
Saarnio et al., “Immunohistochemical study of colorectal tummors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation,”Am J Pathol, 153: 279-285 (1998).
Saarnio et al., “Transmembrane carbonic anhydrase, MN/CA IX, is a potential biomarker for biliary tumors,”J Hepatol, 35: 643-649 (2001).
Swinson et al., “Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia is associated with a poor prognosis in non-small cell lung cancer,”J Clin Oncol, 21: 473-482 (2003).
Turner et al., “MN antigen expression in normal, preneoplastic, and neoplastic esophagus: A clinicopathological study of a new cancer-associated biomarker,”Human Pathol, 28: 740-744 (1997).
Uemura et al., “MN/CA IX/G250 as a potential target for immunotherapy of renal call carcinomas,”Br. J. Cancer, 81:741-746 (1999).
Wykoff et al. “Hypoxia-inducible expression of tumor-associated carbouic anhydrases,”Cancer Res, 60: 7075-7083 (2000).
Zavada et al., “Expression of MaTu-MN protein in human tumor cultures and in clinical specimens,”Int J Cancer, 54: 268-274 (1993).
Zhong et al, “Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases,”Cancer Res, 59: 5830-5835 (1999).
Birner et al., “Expression of Hypoxia-related Tissue Factors Correlates with Diminished Survival of Adjuvantly Treated Patients with Chromosome 1p Aberrant Oligodendrogl
Ebert Matthias
Pastorek Jaromir
Pastorekova Silvia
Röcken Christoph
Zavada Jan
Aeder Sean
Harland Joan C.
Institute of Virology of the Slovak Academy of Sciences
Lauder Leona L.
Shimei Barbara A.
LandOfFree
MN/CA IX and cancer prognosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MN/CA IX and cancer prognosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MN/CA IX and cancer prognosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2791014